Suppr超能文献

体内调节小RNA活性的潜力。

The potential of modulating small RNA activity in vivo.

作者信息

van Mil Alain, Doevendans Pieter A, Sluijter Joost P G

机构信息

University Medical Center Utrecht, Department of Cardiology, DH&L, Heidelberglaan 100, room G02.523, 3584 CX Utrecht, The Nederlands.

出版信息

Mini Rev Med Chem. 2009 Feb;9(2):235-48. doi: 10.2174/138955709787316029.

Abstract

Small RNAs have shown to be ubiquitous, useful, post-transcriptional gene silencers in a diverse array of living organisms. As a result of homologous sequence interactions, these small RNAs repress gene expression. Through a process called RNA interference (RNAi), double strand RNA molecules are processed by an enzyme called Dicer, which cleaves RNA duplexes into 21-23 base pair oligomers. Depending on their end-point functions, these oligomers are named differently, the two most common being small interfering RNAs (siRNAs) and microRNAs (miRNAs). These small RNAs are the effector molecules for inducing RNAi, leading to post-transcriptional gene silencing by guiding the RNAi-induced silencing complex (RISC) to the target mRNA. By exploiting these small RNAs, it is possible to regulate the expression of genes related to human disease. The knockdown of such target genes can be achieved by transfecting cells with synthetically engineered small RNAs or small RNA expressing vectors. Within recent years, studies have also shown the important role of miRNAs in different diseases. By using several chemically engineered anti-miRNA oligonucleotides, disease related miRNAs can be specifically and effectively silenced. Since RNAi has developed into an everyday method for in vitro knockdown of any target gene of interest, the next step is to further explore its potential in vivo and the unique opportunities it holds for the development of novel therapeutic strategies. This review explores the various applications of small RNA technology in in vivo studies, and its potential for silencing genes associated with various human diseases. We describe the latest development in small RNA technology for both gene knockdown, and the inhibition of translational silencing in animal studies. A variety of small RNA formulations and modifications will be reviewed for their improvement on stability and half-life, their safety and off-target effects, and their efficiency and specificity of gene silencing.

摘要

小RNA已被证明是广泛存在于各种生物体内、发挥作用的转录后基因沉默因子。由于同源序列相互作用,这些小RNA会抑制基因表达。通过一种名为RNA干扰(RNAi)的过程,双链RNA分子由一种名为Dicer的酶进行加工,该酶将RNA双链切割成21 - 23个碱基对的寡聚物。根据其终点功能,这些寡聚物有不同的命名,最常见的两种是小干扰RNA(siRNA)和微小RNA(miRNA)。这些小RNA是诱导RNAi的效应分子,通过引导RNAi诱导沉默复合体(RISC)作用于靶mRNA,导致转录后基因沉默。通过利用这些小RNA,可以调节与人类疾病相关基因的表达。通过用合成工程化的小RNA或表达小RNA的载体转染细胞,可以实现此类靶基因的敲低。近年来,研究还表明miRNA在不同疾病中发挥着重要作用。通过使用几种化学工程化的抗miRNA寡核苷酸,可以特异性且有效地沉默与疾病相关的miRNA。由于RNAi已发展成为一种体外敲低任何感兴趣靶基因的日常方法,下一步是进一步探索其在体内的潜力以及它为新型治疗策略开发所带来的独特机遇。本综述探讨了小RNA技术在体内研究中的各种应用,以及其沉默与各种人类疾病相关基因的潜力。我们描述了小RNA技术在动物研究中用于基因敲低和抑制翻译沉默的最新进展。将对多种小RNA制剂和修饰进行综述,以评估它们在稳定性和半衰期、安全性和脱靶效应以及基因沉默效率和特异性方面的改进。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验